What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “INO-9012 delivered by intradermal injection and electroporation”In the company’s words, NCT04251117 on ClinicalTrials.gov
- Tested for
- HCC (2 trials)
- Main trialPhase 2
- “This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine…”In the company’s words, NCT07722741 on ClinicalTrials.gov
Other drugs for HCC
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up1
- Sep 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Sep 2029 | Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC | |
| Phase 1/2Active, not recruiting | 29 Nov 2024 | GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026